SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling

Zhou，Zhongqiu1,2,3; Zhang，Zhuojun1,2; Chen，Han1,2; Bao，Wenhao1,2; Kuang，Xiangqin1,2; Zhou，Ping1,2; Gao，Zhiqing1,2; Li，Difeng1,2; Xie，Xiaoyi1,2; Yang，Chunxiao1,2; Chen，Xuhong4; Pan，Jinyuan5; Tang，Ruiming6; Feng，Zhengfu6; Zhou，Lihuan6; Wang，Lan7; Yang，Jianan1,8; Jiang，Lili1,2

2022

10.1038/s41416-022-01794-7

BRITISH JOURNAL OF CANCER   影响因子和分区

0007-0920

1532-1827

Background: Patients with metastatic bladder cancer have very poor prognosis and predictive biomarkers are urgently needed for early clinical detection and intervention. In this study, we evaluate the effect and mechanism of Suprabasin (SBSN) on bladder cancer metastasis. Methods: A tissue array was used to detect SBSN expression by immunohistochemistry. A tumour-bearing mouse model was used for metastasis evaluation in vivo. Transwell and wound-healing assays were used for in vitro evaluation of migration and invasion. Comprehensive molecular screening was achieved by western blotting, immunofluorescence, luciferase reporter assay, and ELISA. Results: SBSN was found markedly overexpressed in bladder cancer, and indicated poor prognosis of patients. SBSN promoted invasion and metastasis of bladder cancer cells both in vivo and in vitro. The secreted SBSN exhibited identical biological function and regulation in bladder cancer metastasis, and the interaction of secreted SBSN and EGFR could play an essential role in activating the signalling in which SBSN enhanced the phosphorylation of EGFR and SRC kinase, followed with phosphorylation and nuclear location of STAT3. Conclusions: Our findings highlight that SBSN, and secreted SBSN, promote bladder cancer metastasis through activation of EGFR/SRC/STAT3 pathway and identify SBSN as a potential diagnostic and therapeutic target for bladder cancer.

SCI

英语

其他

WOS:000788472500002

CLINICAL MEDICINE

2-s2.0-85129077115

Scopus

1.Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Guangzhou,510095,China
2.Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Science,Guangzhou Medical University,Guangzhou,511436,China
3.Meishan Women and Children’s Hospital,Alliance Hospital of West China Second University Hospital,Sichuan University,Meishan,620000,China
4.Medical Research Center,Southern University of Science and Technology Hospital,Shenzhen,518055,China
5.Department of Oncology,Huanggang Central Hospital of Yangtze University,Huanggang,438000,China
6.The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People’s Hospital,Guangzhou,511518,China
7.Department of Pathogen Biology and Immunology,School of Basic Courses,Guangdong Pharmaceutical University,Guangzhou,510006,China
8.Department of Urologic Oncosurgery,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Guangzhou,510095,China

Zhou，Zhongqiu,Zhang，Zhuojun,Chen，Han,et al. SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling[J]. BRITISH JOURNAL OF CANCER,2022.

Zhou，Zhongqiu.,Zhang，Zhuojun.,Chen，Han.,Bao，Wenhao.,Kuang，Xiangqin.,...&Jiang，Lili.(2022).SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.BRITISH JOURNAL OF CANCER.

Zhou，Zhongqiu,et al."SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling".BRITISH JOURNAL OF CANCER (2022).